Adrafinil vs Sabroxy (Oroxylum indicum)

Mechanism

Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).

Standard Dosing

300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)

Timing

Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.

Cycle Duration

Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.

Side Effects

• All modafinil side effects apply
• Elevated liver enzymes (ALT/AST)
• Potential hepatotoxicity with chronic use
• Skin reactions
• GI distress (more common than with modafinil due to hepatic metabolism)

Contraindications

• Hepatic impairment of any severity
• Concurrent hepatotoxic medication
• All contraindications for modafinil apply (cardiac conditions, anxiety disorders, pregnancy)
• History of liver disease or elevated liver enzymes

Best Stacking Partners

Mechanism

Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.

Contraindications

• Concurrent MAO inhibitors